Keryx Biopharmaceuticals — FY2017 Earnings Presentation
23 slides from Keryx Biopharmaceuticals's earnings presentation, Feb 7, 2018
Slide 1: 4Q and Full Year 2017 Financial Results Call
Keryx biopharmaceuticals 4Q and Full Year 2017 Financial Results Call February 7, 2018 Exhibit 99.2
Slide 2: Agenda
Agenda Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Topic Speakers Welcome Amy Sullivan, SVP, Corporate Affairs Opening Remarks Greg Madison, President & CEO 4Q 2017 Results Scott Holmes, CFO Commercial Progress Doug Jermasek, VP, Marketing & Strategy Question & Answer All
Slide 3: Forward-Looking Statements
Forward-Looking Statements Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development of Auryxia, including statements with respect to the demand and growth of Auryxia pa
Slide 4: Opening remarks
Opening remarks Greg Madison, CEO
Slide 5: Fourth Quarter – A Strong Finish to 2017
Fourth Quarter – A Strong Finish to 2017 Received FDA approval for a second indication for Auryxia® for the treatment of iron deficiency anemia in patients with CKD, not on dialysis Delivered strong Auryxia demand growth for the treatment of hyperphosphatemia Launched Auryxia for our second indicati
Slide 6: Second Indication for Auryxia
Second Indication for Auryxia® Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Second Indication: treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD), not on dialysis Label supports use of Auryxia as a first-line treatment option Auryxia’s expanded indication n
Slide 7: 4Q17 Results
4Q17 REsults Scott Holmes, CFO
Slide 8: 4Q 2017 Prescription and Revenue Growth Highlights
4Q 2017 Prescription and Revenue Growth Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Highlights 22% growth in prescriptions from 3Q 4Q17 net product revenue of $17.3 million Gross-to-net adjustment stabilized in 4Q (54%) IMS/Specialty mix: 56%/44% Absolute inventory levels were flat compared t
Slide 9: Commercial Performance Metrics
Commercial Performance Metrics Copyright © 2018 by Keryx Biopharmaceuticals, Inc. 2017 Quarterly Auryxia Market Share Calcium Acetate Auryxia Sevelamer* Lanthanum** Velphoro % TRx Change 4Q17 vs 3Q17 Highlights Auryxia market share: >4% Fastest growing phosphate binder * Includes generics and brande
Slide 10: Selected Financial Results
Selected Financial Results Copyright © 2018 by Keryx Biopharmaceuticals, Inc. ($ in millions, except per share amounts) Three Months Ended Dec. 31, 2017 (unaudited) Three Months Ended Dec. 31, 2016 (unaudited) Year Ended Dec. 31, 2017 (unaudited) Year Ended Dec. 31, 2016 (audited) Net U.S. Auryxia P
Slide 11: Dynamics Related to Iron Deficiency Anemia
Dynamics Related to Iron Deficiency Anemia Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Expect the IMS Rx capture rate to increase over time Demand tablets vs. Rxs will better correlate to brand performance Starting doses are different between the two indications Gross to net adjustment stabil
Slide 12: Commercial Progress
Commercial Progress Doug Jermasek, VP of Marketing and Strategy
Slide 13: Auryxia Offers Continuity of Care
Auryxia Offers Continuity of Care Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Progressing patients typically referred to nephrologist Prepare for renal replacement therapy Patients initiate dialysis GFR (mL/min) Often not diagnosed Patients typically under care of PCP Patients typically under
Slide 14: Today's Focus: Nephrology
Copyright © 2018 by Keryx Biopharmaceuticals, Inc. 650,000 Non-dialysis CKD, Iron Deficiency Anemia (treated) 700,000 Non-dialysis CKD (untreated) 400,000 Non-dialysis CKD, Iron Deficiency Anemia (untreated) 70,000 - Dialysis not on Binder 380,000 Dialysis (treated with binder) 2.2 million under car
Slide 15: Our Market Approach to Hyperphosphatemia
Today’s Focus: Nephrology Our Market Approach to Hyperphosphatemia Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Clinical Challenge: 30-40% of people have uncontrolled phosphorus levels; associated with higher rates of morbidity and mortality Greatest challenge: Patient adherence (pill burden &
Slide 16: Our Market Approach to Iron Deficiency Anemia
Today’s Focus: Nephrology Our Market Approach to Iron Deficiency Anemia Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Clinical Challenge: Prevalent, significant and highly symptomatic Associated w/cardiovascular disease & reduced quality of life Guidelines recommend oral iron first Greatest cha
Slide 17: Key Iron Deficiency Launch Objectives
Key Iron Deficiency Launch Objectives Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Drive rapid awareness of new indication in iron deficiency anemia Differentiate Auryxia from existing treatment options Communicate favorable reimbursement access to Auryxia
Slide 18: Iron Deficiency Anemia Promotion Market Research Highlights
Iron Deficiency Anemia Promotion Market Research Highlights* Awareness of Auryxia’s new indication is strong 80% of nephrologists are aware of Auryxia’s indication for iron deficiency anemia in patients with CKD not on dialysis. Auryxia representative call rates are high Share of voice has increased
Slide 19: Future Opportunity: Reach Beyond Nephrology
Future Opportunity Auryxia’s Expanded Label Supports Reach Beyond Nephrology Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Growth Opportunity ~14 million people with CKD not under care of nephrologist are iron deficient Potential to extend reach to non-nephrology targets Source: Keryx Data on F
Slide 20: Closing remarks
Closing remarks Greg Madison
Slide 21: 2018 Keryx Objectives
2018 Keryx Objectives Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Increase number of patients treated with Auryxia Drive rapid awareness of IDA indication and differentiate from existing treatment options Continued growth in dialysis Assess opportunity for Auryxia outside of nephrology Explor
Slide 22: Strong Foundation to Build a Leading Kidney Care Company
Strong Foundation to Build a Leading Kidney Care Company Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Phosphate Management Anemia Management THANK YOU!
Slide 23: Keryx
KK KERYX X RMACEUTICALS,ING
Keryx Biopharmaceuticals — FY2017 Earnings Presentation on 6ix